The prospective ORAL surveillance trial revealed that MACEs occurred more often with tofacitinib than with a TNF inhibitor in aged patients with RA and underlying CV risk factors; thus, it might not capture the real-world risk for MACEs in patients without underlying CVDs at treatment initiation (Ytterberg et al., 2022). Here, TNF is linked to rheumatoid arthritis.